Skip to content

Crizotinib

Xalkori (crizotinib) is a small molecule pharmaceutical. Crizotinib was first approved as Xalkori on 2011-08-26. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor. Xalkori's patents are valid until 2029-11-06 (FDA).
Trade Name Xalkori
Common Name Crizotinib
Indication non-small-cell lung carcinoma
Drug Class Tyrosine kinase inhibitors
Crizotinib
Get full access now